MannKind Corporation stocks have been trading up by 3.02 percent, buoyed by strong Afrezza demand and improved revenue outlook.
Click Here for a Millionaire's POV on Trading MNKD
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- MannKind will present nine new Afrezza and FUROSCIX data sets at ADA 2026, including pediatric, gestational diabetes, automated insulin delivery, and real‑world outcome data.
- The Afrezza pediatric sBLA faces an FDA PDUFA decision on 2026/05/29 that could make it the first needle‑free insulin for children and adolescents and expand its addressable market if approved.
- A CEO fireside chat at the 2026 Jefferies Global Healthcare Conference will highlight MannKind’s cardiometabolic and orphan lung disease strategy and its drug‑device platform.
- Multiple Form 4 filings show insider ownership changes in MannKind shares, but with no disclosed size, direction, or rationale, limiting their trading signal.
Weekly Update May 25 – May 29, 2026: On Friday, May 29, 2026 MannKind Corporation stock [NASDAQ: MNKD] is trending up by 3.02%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
MannKind operates a niche, late-commercial respiratory drug–device franchise with strong top-line momentum but weak profitability. Revenue of ~$349M and 3-year CAGR above 40% signal real commercial traction, yet EBIT margin (-6.6%) and negative ROA underscore an unfinished transition to sustainable earnings. Gross margin near 100% is inflated by collaboration/royalty mix but still highlights attractive unit economics. Balance sheet risk is material: negative equity, long-term debt of ~$329M, and interest expense outpacing operating income.
Technically, MNKD shows a short-term uptrend: the weekly sequence from 3.54 to 3.75 reflects consistent higher closes and tightening intraday ranges, suggesting steady accumulation rather than speculative spikes. Five‑minute candles recently held bids above 3.70 on dips, with increasing volume on pushes through 3.75–3.80, defining that band as near-term resistance. The actionable level is support at ~3.55; active traders can buy pullbacks toward 3.55–3.60 with a tight stop below 3.45 and trim into 3.80–3.90.
More Breaking News
- SPCE Stock Jumps As Virgin Galactic Ramps Toward 2026 Launch
- AVAV Jumps As U.S. Boosts Freedom Eagle-1 Funding
- Opendoor Technologies Stock Jumps As Turnaround Story Gains Traction
- BNRG Stock Slides As Resale Registration Adds Supply Overhang
The Afrezza pediatric sBLA with a May 29, 2026 PDUFA is a high‑impact binary catalyst that, if approved, broadens Afrezza’s addressable market and should re-rate MNKD versus small‑cap biotech peers, where pediatric type 1 diabetes access is a scarce asset. Additional ADA 2026 data across pediatrics, gestational diabetes, and automated insulin delivery integration can strengthen the adoption narrative. Relative to healthcare and biotech indices, MNKD remains higher risk but with superior revenue growth. I expect a constructive skew with near-term support at 3.40, resistance at 4.25, and a 6–12 month upside target of 5.00 contingent on pediatric approval and execution.
Quick Financial Overview
MannKind Corporation (MNKD) sits in an interesting spot where catalysts and charts are starting to line up. On the weekly tape, the stock has pushed from the mid‑$3.50s to close near $3.75–$3.83, a steady grind that signals quiet accumulation rather than a blow‑off move. Intraday 5‑minute action shows a tight intraday range with repeated holds above $3.70 and afternoon pushes toward $3.85–$3.90, telling traders that dip buyers are active and sellers are not pressing hard yet.
On the fundamentals, MannKind delivered about $349.0M in trailing revenue with roughly 41% three‑ and five‑year growth, but it is still losing money. Last quarter’s total revenue of $90.2M produced a gross margin near 99.7%, yet operating income was about -$1.7M and net income roughly -$16.6M, reflecting heavy selling and R&D spend. The company’s current ratio around 1.9 and cash plus short‑term investments of about $133.9M provide a liquidity cushion, even as free cash flow for the quarter was about -$7.2M.
Valuation is tricky here. With a price‑to‑sales ratio near 3.0 and negative earnings, MannKind trades as a classic catalyst‑driven biotech rather than a steady cash machine. Return on assets is negative (around -6% to -7%), and book value per share is slightly below zero, so traders cannot lean on traditional value metrics. Instead, the real levers are Afrezza and FUROSCIX growth, upcoming ADA 2026 data, and the pediatric Afrezza PDUFA on 2026/05/29, which could reset sentiment and volume as that date approaches.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.